People with schizophrenia die 15‐20 years prematurely. Understanding mortality risk and
aggravating/attenuating factors is essential to reduce this gap. We conducted a systematic …

Schizophrenia research has traditionally focused almost exclusively on how the brain
interprets the outside world. However, our internal bodily milieu is also central to how we …

Orally administered antipsychotic drugs are the first-line treatment for psychotic disorders,
such as schizophrenia and bipolar disorder. Nevertheless, adverse drug reactions …

Mental disorders are the leading contributors to the globally nonfatal burden of disease. This
study was aimed to estimate the burden of mental disorders in Asian countries. Based on …

AimsCardiometabolic diseases are responsible for the majority of premature deaths in
people with schizophrenia. This study aimed to quantify the fatal burden of ischaemic heart …

Objectives This study aimed to assess weight changes following antipsychotic treatment in
first-episode schizophrenia (FES) patients and make a comparison of aripiprazole …

Background Few investigations have been carried out on metabolic syndrome in
antipsychotic-naïve patients with schizophrenia. Methods Our primary objective was to …

Women with schizophrenia have specific health needs that differ from those of men and that
change through successive life stages. We aimed to review the biopsychosocial literature on …

Background Schizophrenia is associated with increased risk of developing multiple aging-
related diseases, including metabolic, respiratory, and cardiovascular diseases, and …

The nasal breathing parameters have shown promising applications in hyperventilation,
Kussmaul breathing, sleep apnea, shortness of breath in COVID-19, bradypnea, sinus …